Clinical trial
Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
NCT01373281 is registered in ClinicalTrials.gov with Sanofi Pasteur, a Sanofi Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 3, 2011
- Completion date
- November 21, 2017
- Enrollment
- 10,275 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.
dengue, dengue fever, dengue hemorrhagic fever